-
DFCP1 Regulates ATGL-Driven Lipid Droplet Lipolysis During S
2026-06-10
This study uncovers Double FYVE Domain Containing Protein 1 (DFCP1) as a direct regulator of ATGL-mediated lipid droplet (LD) catabolism in response to nutrient deprivation. By mechanistically linking DFCP1 to ATGL recruitment and activity, the research advances our molecular understanding of cellular lipid mobilization and offers a framework for optimizing protein stability protocols in lipid metabolism studies.
-
Liproxstatin-1: Potent Ferroptosis Inhibitor for Precision R
2026-06-10
Liproxstatin-1 is a potent ferroptosis inhibitor that blocks lipid peroxidation and protects against iron-dependent cell death with nanomolar potency. It enables precise modulation of ferroptosis in both in vitro and in vivo models, supporting robust research into regulated cell death mechanisms.
-
RepSox ALK5 Inhibitor: Streamlining iPSC Platelet Generation
2026-06-09
RepSox, a potent and selective ALK5 inhibitor from APExBIO, is transforming induced pluripotent stem cell (iPSC) workflows by enabling cost-effective, high-yield platelet production. This article decodes the latest protocol enhancements, actionable troubleshooting, and advanced applications that maximize RepSox’s impact in cell differentiation and TGF-β pathway inhibition research.
-
Optimizing Thrombin-Based Workflows: Applied Use-Cases & Tro
2026-06-09
Unlock the full potential of APExBIO's ultra-pure thrombin B chain fragment in advanced coagulation, vascular, and cell-based assays. This guide delivers actionable protocols and troubleshooting insights, bridging mechanistic understanding with reproducible experimental success.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract
2026-06-08
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is designed to prevent unwanted protein degradation during extraction and analysis, especially in workflows where EDTA is incompatible, such as phosphorylation or kinase assays. It should not be used where DMSO is disruptive or protease inhibition is unnecessary.
-
Streptavidin-Cy3 (SKU K1079): Precision Biotin Detection in
2026-06-08
This article guides bench scientists through genuine workflow challenges in cell viability and gene regulation assays, demonstrating how Streptavidin-Cy3 (SKU K1079) enhances sensitivity, reproducibility, and interpretability. Through scenario-driven Q&A, we detail protocol best practices, data clarity, and practical vendor selection, with actionable links to validated performance data and protocols.
-
Optimizing PCR and DNA Synthesis with 10 mM dNTP Mixture
2026-06-07
Unlock high-fidelity DNA synthesis and robust PCR performance with the 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture. Explore advanced workflow enhancements, troubleshooting insights, and cross-domain applications powered by APExBIO's rigorously formulated molecular biology reagent.
-
Carboplatin in Oncology: Proteomics-Driven Insights for Prec
2026-06-06
Explore how Carboplatin, a platinum-based DNA synthesis inhibitor, shapes preclinical oncology research through cutting-edge proteomics and dimensional cell culture models. Uncover crucial assay considerations and new directions for overcoming resistance.
-
Synergistic Colistin-Gamithromycin Therapy in Murine Lung In
2026-06-05
The study demonstrates that combining colistin with gamithromycin dramatically enhances antimicrobial efficacy against Pasteurella multocida in a neutropenic murine lung infection model, particularly for strains with high colistin resistance. This combinatorial approach not only reduces required drug dosages but also offers a promising strategy to counteract antimicrobial resistance in respiratory pathogens of veterinary importance.
-
Reserpine (N1867): Technical Protocols for Lab Researchers
2026-06-05
Reserpine (SKU N1867) is a high-purity, research-grade natural product widely used to model neurotransmitter depletion and antihypertensive mechanisms in neuropharmacology. It is not suitable for diagnostic or clinical applications, and strict adherence to preparation and storage protocols is required to ensure reproducible results.
-
Mitomycin C in Cancer Research: Protocols, Pitfalls, and Inn
2026-06-04
Mitomycin C stands out as a benchmark antitumor antibiotic, enabling precise DNA replication inhibition and advanced apoptosis signaling research. This guide unpacks optimized protocols, troubleshooting strategies, and practical insights for maximizing Mitomycin C’s impact in cancer and apoptosis research workflows.
-
Mitomycin C: Precision DNA Inhibition for Translational Rese
2026-06-04
Explore how Mitomycin C, a gold-standard antitumor antibiotic, is redefining apoptosis signaling and DNA replication inhibition in translational cancer research. This article bridges mechanistic insight with actionable guidance, spotlighting experimental nuances, competitive positioning, and a future-focused outlook for researchers seeking to optimize their workflows with APExBIO's Mitomycin C.
-
Biomimetic Chromatography Models Pulmonary Drug Permeability
2026-06-03
This study benchmarks biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane chromatography (IAM-LC) coupled with mass spectrometry for modeling lung drug permeability. The findings highlight IAM-LC’s strong predictive power for pulmonary absorption and outline practical advances for high-throughput permeability screening.
-
Parathyroid hormone (1-34) (human) in Advanced Bone & Kidney
2026-06-03
Parathyroid hormone (1-34) (human) empowers high-fidelity modeling of calcium homeostasis, bone metabolism, and kidney disease. Learn how precise protocols, troubleshooting insights, and mechanistic data unlock reproducible, next-generation workflows for osteoporosis and CKD-related research.
-
Dual “Engage & Evasion” Strategy Enhances EV Therapy in Isch
2026-06-02
Liu et al. introduce a two-step 'Engage & Evasion' approach to overcome rapid mononuclear phagocyte system (MPS) clearance of extracellular vesicles (EVs), significantly improving EV biodistribution and therapeutic efficacy for ischemic disease models. This work pioneers a sequential saturation and evasion methodology, addressing a core translational barrier for EV-based therapies.